U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H37N5O5S
Molecular Weight 579.71
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TMC-558445

SMILES

CCN(C)C1=NC2=CC=C(C=C2O1)C(=O)N(CC(C)C)C[C@@H](O)[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4

InChI

InChIKey=RGTBBKSFLZZHLT-IZZNHLLZSA-N
InChI=1S/C30H37N5O5S/c1-5-34(4)29-32-24-12-11-22(14-27(24)40-29)28(37)35(16-20(2)3)17-26(36)25(13-21-9-7-6-8-10-21)33-30(38)39-18-23-15-31-19-41-23/h6-12,14-15,19-20,25-26,36H,5,13,16-18H2,1-4H3,(H,33,38)/t25-,26+/m0/s1

HIDE SMILES / InChI

Molecular Formula C30H37N5O5S
Molecular Weight 579.71
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:37:34 UTC 2023
Edited
by admin
on Sat Dec 16 11:37:34 UTC 2023
Record UNII
QJ6KY7R5SS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TMC-558445
Common Name English
(1,3-THIAZOL-5-YL)METHYL N-((2S,3R)-4-(1-(2-(ETHYL(METHYL)AMINO)-1,3-BENZOXAZOL-6-YL)-N-(2-METHYLPROPYL)FORMAMIDO)-3-HYDROXY-1-PHENYLBUTAN-2-YL)CARBAMATE
Systematic Name English
CARBAMIC ACID, N-((1S,2R)-3-(((2-(ETHYLMETHYLAMINO)-6-BENZOXAZOLYL)CARBONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-, 5-THIAZOLYLMETHYL ESTER
Systematic Name English
THIAZOL-5-YLMETHYL N-((1S,2R)-1-BENZYL-3-((2-(ETHYL(METHYL)AMINO)-1,3-BENZOXAZOLE-6-CARBONYL)-ISOBUTYL-AMINO)-2-HYDROXY-PROPYL)CARBAMATE
Systematic Name English
Code System Code Type Description
PUBCHEM
42609861
Created by admin on Sat Dec 16 11:37:35 UTC 2023 , Edited by admin on Sat Dec 16 11:37:35 UTC 2023
PRIMARY
FDA UNII
QJ6KY7R5SS
Created by admin on Sat Dec 16 11:37:35 UTC 2023 , Edited by admin on Sat Dec 16 11:37:35 UTC 2023
PRIMARY
CAS
1160489-55-3
Created by admin on Sat Dec 16 11:37:35 UTC 2023 , Edited by admin on Sat Dec 16 11:37:35 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
PHARMAKINETIC ENHANCER
Related Record Type Details
ACTIVE MOIETY
TMC-558445 manufactured by Tibotec pharmaceuticals is currently being tested in a phase-I study. Results are not available yet. At CROI in February 2009, new pharmacoenhancers were introduced for the first time that could challenge ritonavirs booster monopoly. The advantages of these new agents inhibiting the CYP3A system is that they have no antiviral effect and thus cannot cause resistance. Obviously, there are no reports yet about long-term side effects and the effects of such a total inhibition of enzyme systems.